Ferran Navarro

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4455612/publications.pdf

Version: 2024-02-01

139 papers	6,501 citations	57758 44 h-index	79698 73 g-index
161 all docs	161 docs citations	161 times ranked	7554 citing authors

#	Article	IF	Citations
1	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	9.1	367
2	Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. Nature, 2021, 595, 707-712.	27.8	363
3	Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clinical Microbiology and Infection, 2010, 16, 112-122.	6.0	287
4	Isolation and Characterization of Potentially Pathogenic Antimicrobial-Resistant Escherichia coli Strains from Chicken and Pig Farms in Spain. Applied and Environmental Microbiology, 2010, 76, 2799-2805.	3.1	207
5	Extended-spectrum Â-lactamase-producing Enterobacteriaceae in different environments (humans,) Tj ETQq1 1 0.784314 rgBT /Overlo	3.0	199
6	Extended-spectrum Î²-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. International Journal of Antimicrobial Agents, 2009, 34, 173-176.	2.5	164
7	Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa Isolates from Spanish Hospitals. Antimicrobial Agents and Chemotherapy, 2007, 51, 4329-4335.	3.2	161
8	A Multinational, Preregistered Cohort Study of Î²-Lactam/Î²-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	3.2	137
9	Metallo-Î²-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. International Journal of Antimicrobial Agents, 2007, 29, 380-388.	2.5	134
10	ESBL- and plasmidic class C Î²-lactamase-producing E. coli strains isolated from poultry, pig and rabbit farms. Veterinary Microbiology, 2006, 118, 299-304.	1.9	133
11	Prospective Multicenter Study of Carbapenemase-Producing Enterobacteriaceae from 83 Hospitals in Spain Reveals High In Vitro Susceptibility to Colistin and Meropenem. Antimicrobial Agents and Chemotherapy, 2015, 59, 3406-3412.	3.2	130
12	Antibiotic Resistance Trends in Enteropathogenic Bacteria Isolated in 1985â€“1987 and 1995â€“1998 in Barcelona. Antimicrobial Agents and Chemotherapy, 2000, 44, 1140-1145.	3.2	126
13	Cloning and Sequence of the Gene Encoding a Novel Cefotaxime-Hydrolyzing Î²-Lactamase (CTX-M-9) from Escherichia coli in Spain. Antimicrobial Agents and Chemotherapy, 2000, 44, 1970-1973.	3.2	121
14	Antibiotic Resistance Genes in the Bacteriophage DNA Fraction of Human Fecal Samples. Antimicrobial Agents and Chemotherapy, 2014, 58, 606-609.	3.2	105
15	Prevalence and molecular epidemiology of acquired AmpC Î²-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 253-259.	2.9	91
16	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	3.0	89
17	Novel Complex sul1 -Type Integron in Escherichia coli Carrying bla CTX-M-9. Antimicrobial Agents and Chemotherapy, 2002, 46, 2656-2661.	3.2	86
18	Bacteriophages in clinical samples can interfere with microbiological diagnostic tools. Scientific Reports, 2016, 6, 33000.	3.3	86

#	Article	IF	Citations
19	Phages in the Human Body. Frontiers in Microbiology, 2017, 8, 566.	3.5	86
20	Characterisation of the CTX-M-15-encoding gene in Klebsiella pneumoniae strains from the Barcelona metropolitan area: plasmid diversity and chromosomal integration. International Journal of Antimicrobial Agents, 2010, 36, 73-78.	2.5	85
21	Bacteriophages and Diffusion of Î²-lactamase Genes. Emerging Infectious Diseases, 2004, 10, 1134-1137.	4.3	83
22	Epidemiology of Clostridium difficile Infection and Risk Factors for Unfavorable Clinical Outcomes: Results of a Hospital-Based Study in Barcelona, Spain. Journal of Clinical Microbiology, 2013, 51, 1465-1473.	3.9	80
23	Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. Journal of Infection, 2016, 72, 152-160.	3.3	73
24	Surveillance of extended-spectrum Î²-lactamases from clinical samples and faecal carriers in Barcelona, Spain. Journal of Antimicrobial Chemotherapy, 2005, 56, 1152-1155.	3.0	70
25	Community Transmission of Extended-Spectrum ÃŸ-Lactamase. Emerging Infectious Diseases, 2003, 9, 1024-1025.	4.3	69
26	Characterization of plasmids encoding blaESBL and surrounding genes in Spanish clinical isolates of Escherichia coli and Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2008, 63, 60-66.	3.0	66
27	Characterization of Aminoglycoside-Modifying Enzymes inEnterobacteriaceaeClinical Strains and Characterization of the Plasmids Implicated in Their Diffusion. Microbial Drug Resistance, 2013, 19, 94-99.	2.0	66
28	Superantigen gene profile, emm type and antibiotic resistance genes among group A streptococcal isolates from Barcelona, Spain. Journal of Medical Microbiology, 2006, 55, 1115-1123.	1.8	64
29	Rapid detection of specific gene mutations associated with isoniazid or rifampicin resistance in Mycobacterium tuberculosis clinical isolates using non-fluorescent low-density DNA microarrays. Journal of Antimicrobial Chemotherapy, 2006, 57, 825-831.	3.0	63
30	Escherichia coli Serotype O15:K52:H1 as a Uropathogenic Clone. Journal of Clinical Microbiology, 2000, 38, 201-209.	3.9	63
31	Spread of plasmids containing the blaVIM-1 and blaCTX-M genes and the qnr determinant in Enterobacter cloacae, Klebsiella pneumoniae and Klebsiella oxytoca isolates. Journal of Antimicrobial Chemotherapy, 2010, 65, 661-665.	3.0	62
32	Dissemination of extended-spectrum Â-lactamase-producing bacteria: the food-borne outbreak lesson. Journal of Antimicrobial Chemotherapy, 2008, 61, 1244-1251.	3.0	59
33	In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens. Scientific Reports, 2020, 10, 7163.	3.3	54
34	First Detection of a Carbapenem-Hydrolyzing Metalloenzyme in Two Enterobacteriaceae Isolates in Spain. Antimicrobial Agents and Chemotherapy, 2005, 49, 3492-3494.	3.2	53
35	Plasmid typing and genetic context of AmpC Î²-lactamases in Enterobacteriaceae lacking inducible chromosomal ampC genes: findings from a Spanish hospital 1999â€“2007. Journal of Antimicrobial Chemotherapy, 2012, 67, 115-122.	3.0	53
36	Acquisition and diffusion of blaCTX-M-9 gene by R478-IncHI2 derivative plasmids. FEMS Microbiology Letters, 2007, 271, 71-77.	1.8	52

#	Article	IF	Citations
37	Increase in Quinolone Resistance in a Haemophilus influenzae Strain Isolated from a Patient with Recurrent Respiratory Infections Treated with Ofloxacin. Antimicrobial Agents and Chemotherapy, 1999, 43, 161-162.	3.2	51
38	Shiga Toxin 2-Encoding Bacteriophages in Human Fecal Samples from Healthy Individuals. Applied and Environmental Microbiology, 2013, 79, 4862-4868.	3.1	50
39	Spanish Multicenter Study of the Epidemiology and Mechanisms of Amoxicillin-Clavulanate Resistance in Escherichia coli. Antimicrobial Agents and Chemotherapy, 2012, 56, 3576-3581.	3.2	49
40	Molecular diagnosis of bloodstream infections with a new dual-priming oligonucleotide-based multiplex PCR assay. Journal of Medical Microbiology, 2013, 62, 1673-1679.	1.8	49
41	Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. Bone Marrow Transplantation, 2015, 50, 579-584.	2.4	49
42	Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant Î²-Lactam Resistance Mechanisms. Antimicrobial Agents and Chemotherapy, 2016, 60, 6407-6410.	3.2	47
43	Antibiotic resistance genes in phage particles isolated from human faeces and induced from clinical bacterial isolates. International Journal of Antimicrobial Agents, 2018, 51, 434-442.	2.5	46
44	Prevalence of SXT/R391-like integrative and conjugative elements carrying blaCMY-2 in Proteus mirabilis. Journal of Antimicrobial Chemotherapy, 2011, 66, 2266-2270.	3.0	45
45	Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC Î²-lactamases. Journal of Infection, 2012, 64, 176-183.	3.3	45
46	beta-Lactamases involved in resistance to broad-spectrum cephalosporins in Escherichia coli and Klebsiella spp. clinical isolates collected between 1994 and 1996, in Barcelona (Spain). Journal of Antimicrobial Chemotherapy, 2002, 49, 989-997.	3.0	44
47	Evolution of carbapenemase-producing Enterobacteriaceae at the global and national level: What should be expected in the future?. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2014, 32, 17-23.	0.5	43
48	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum Î²-Lactamaseâ€“Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	5.8	43
49	Prevalence of acquired AmpC Î²-lactamases in Enterobacteriaceae lacking inducible chromosomal ampC genes at a Spanish hospital from 1999 to 2007. Clinical Microbiology and Infection, 2010, 16, 472-476.	6.0	41
50	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	3.0	41
51	Bacterial DNA in the diagnosis of spontaneous bacterial peritonitis. Alimentary Pharmacology and Therapeutics, 2011, 33, 275-284.	3.7	40
52	Population Structure, Antimicrobial Resistance, and Virulence-Associated Genes in Campylobacter jejuni Isolated From Three Ecological Niches: Gastroenteritis Patients, Broilers, and Wild Birds. Frontiers in Microbiology, 2018, 9, 1676.	3.5	40
53	Prevalence of Clinical Isolates of Escherichia coli Producing Inhibitor-Resistant Î²-Lactamases at a University Hospital in Barcelona, Spain, over a 3-Year Period. Antimicrobial Agents and Chemotherapy, 2002, 46, 3991-3994.	3.2	38
54	Diagnostic accuracy of a 16S ribosomal DNA gene-based molecular technique (RT-PCR, microarray, and) Tj ETQq0 0 0 rgBT /Overlock 10 peritonitis. Diagnostic Microbiology and Infectious Disease, 2011, 69, 153-160.	1.8	38

#	Article	IF	Citations
55	Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction. Journal of Antimicrobial Chemotherapy, 1998, 42, 535-538.	3.0	37
56	Characterization of the highly variable region surrounding the blaCTX-M-9 gene in non-related Escherichia coli from Barcelona. Journal of Antimicrobial Chemotherapy, 2005, 56, 819-826.	3.0	37
57	Molecular identification of aminoglycoside-modifying enzymes in clinical isolates of Escherichia coli resistant to amoxicillin/clavulanic acid isolated in Spain. International Journal of Antimicrobial Agents, 2015, 46, 157-163.	2.5	36
58	Core/Whole Genome Multilocus Sequence Typing and Core Genome SNP-Based Typing of OXA-48-Producing Klebsiella pneumoniae Clinical Isolates From Spain. Frontiers in Microbiology, 2019, 10, 2961.	3.5	35
59	The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant. Nature Genetics, 2021, 53, 1405-1414.	21.4	35
60	Are There Regional Variations in the Diagnosis, Surveillance, and Control of Methicillin-ResistantStaphylococcus aureus?. Infection Control and Hospital Epidemiology, 2003, 24, 334-341.	1.8	34
61	Increase in Â-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type Â-lactamases. Journal of Antimicrobial Chemotherapy, 2008, 61, 1029-1032.	3.0	34
62	A simple phenotypic method for differentiation between acquired and chromosomal AmpC Î²-lactamases in Escherichia coli. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2006, 24, 370-372.	0.5	33
63	Lymphadenopathy Caused by Mycobacterium colombiense. Journal of Clinical Microbiology, 2008, 46, 1885-1887.	3.9	31
64	Cephalosporin-resistantEscherichia coliamong Summer Camp Attendees with Salmonellosis. Emerging Infectious Diseases, 2003, 9, 1273-1280.	4.3	29
65	Epidemiological characteristics and outcomes of COVID-19 cases: mortality inequalities by socio-economic status, Barcelona, Spain, 24 February to 4 May 2020. Eurosurveillance, 2021, 26, .	7.0	28
66	In Vitro Activity of the Active Metabolite of Prulifloxacin (AF 3013) Compared with Six Other Fluoroquinolones. European Journal of Clinical Microbiology and Infectious Diseases, 2002, 21, 328-334.	2.9	27
67	Efficacy of the FilmArray blood culture identification panel for direct molecular diagnosis of infectious diseases from samples other than blood. Journal of Medical Microbiology, 2015, 64, 1481-1488.	1.8	27
68	Evidence for convergent evolution of CTX-M-14 ESBL inEscherichia coliand its prevalence. FEMS Microbiology Letters, 2007, 273, 120-123.	1.8	26
69	Detection of three stable genetic clones of CTX-M-15-producing Klebsiella pneumoniae in the Barcelona metropolitan area, Spain. Journal of Antimicrobial Chemotherapy, 2009, 64, 862-864.	3.0	26
70	The Carbapenemase-Producing Klebsiella pneumoniae Population Is Distinct and More Clonal than the Carbapenem-Susceptible Population. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	26
71	Prevalence of Aminoglycoside-Modifying Enzymes in Escherichia coli and Klebsiella pneumoniae Producing Extended Spectrum Î²-Lactamases Collected in Two Multicenter Studies in Spain. Microbial Drug Resistance, 2018, 24, 367-376.	2.0	26
72	Differential Distribution of the wlaN and cgtB Genes, Associated with Guillain-BarrÃ© Syndrome, in Campylobacter jejuni Isolates from Humans, Broiler Chickens, and Wild Birds. Microorganisms, 2020, 8, 325.	3.6	25

#	Article	IF	Citations
73	Multiclonal epidemic of Klebsiella pneumoniae isolates producing DHA-1 in a Spanish hospital. Clinical Microbiology and Infection, 2011, 17, 1032-1036.	6.0	24
74	Faecal phageome of healthy individuals: presence of antibiotic resistance genes and variations caused by ciprofloxacin treatment. Journal of Antimicrobial Chemotherapy, 2019, 74, 854-864.	3.0	24
75	Unravelling the consequences of the bacteriophages in human samples. Scientific Reports, 2020, 10, 6737.	3.3	24
76	Inhibitor-Resistant TEM- and OXA-1-Producing Escherichia coli Isolates Resistant to Amoxicillin-Clavulanate Are More Clonal and Possess Lower Virulence Gene Content than Susceptible Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 3874-3881.	3.2	23
77	Outbreak of Pseudomonas fluorescens bloodstream infection in a coronary care unit. Journal of Hospital Infection, 2012, 82, 286-289.	2.9	22
78	Molecular characterisation of acquired and overproduced chromosomal blaAmpC in Escherichia coli clinical isolates. International Journal of Antimicrobial Agents, 2016, 47, 62-68.	2.5	22
79	Genomic analysis of 40 prophages located in the genomes of 16 carbapenemase-producing clinical strains of Klebsiella pneumoniae. Microbial Genomics, 2020, 6, .	2.0	21
80	Characterisation of fluoroquinolone-resistant clinical isolates of Streptococcus pyogenes in Barcelona, Spain. Clinical Microbiology and Infection, 2005, 11, 759-761.	6.0	20
81	Identification of Trypanosoma cruzi Discrete Typing Units (DTUs) in Latin-American migrants in Barcelona (Spain). Parasitology International, 2017, 66, 83-88.	1.3	20
82	CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3. Frontiers in Microbiology, 0, 13, .	3.5	20
83	Increased resistance to quinolone in Catalonia, Spain. Diagnostic Microbiology and Infectious Disease, 1993, 16, 137-139.	1.8	19
84	In vivoâ€ƒtransmission of a plasmid coharbouring blaDHA-1 and qnrB genes between Escherichia coliâ€ƒand Serratia marcescens. FEMS Microbiology Letters, 2010, 308, 24-28.	1.8	19
85	Mobile Genetic Elements Related to the Diffusion of Plasmid-Mediated AmpC Î²-Lactamases or Carbapenemases from Enterobacteriaceae: Findings from a Multicenter Study in Spain. Antimicrobial Agents and Chemotherapy, 2015, 59, 5260-5266.	3.2	19
86	Bloodstream infections caused by Escherichia coli producing AmpC Î²-lactamases: epidemiology and clinical features. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 1997-2003.	2.9	19
87	The Identification of Intrinsic Chloramphenicol and Tetracycline Resistance Genes in Members of the Bacillus cereus Group (sensu lato). Frontiers in Microbiology, 2016, 7, 2122.	3.5	19
88	Association of blaDHA-1 and qnrB genes carried by broad-host-range plasmids among isolates of Enterobacteriaceae at a Spanish hospital. Clinical Microbiology and Infection, 2011, 17, 1514-1517.	6.0	18
89	Epidemiology and risk factors for infections due to AmpC Â-lactamase-producing Escherichia coli. Journal of Antimicrobial Chemotherapy, 2015, 70, 899-904.	3.0	18
90	Benefits and drawbacks of molecular techniques for diagnosis of viral respiratory infections. Experience with two multiplex PCR assays. Journal of Medical Virology, 2016, 88, 45-50.	5.0	18

#	Article	IF	Citations
91	First Description ofbla_{NDM-7}Carried on an IncX4 Plasmid inEscherichia coliST679 Isolated in Spain. Microbial Drug Resistance, 2018, 24, 113-119.	2.0	18
92	Molecular characterization of OXA-48 carbapenemase-producing Klebsiella pneumoniae strains after a carbapenem resistance increase in Catalonia. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 82-88.	0.5	18
93	Escherichia coli bacteraemia. Serotype O15:K52:H1 as a urinary pathogen. Journal of Hospital Infection, 1996, 34, 233-234.	2.9	17
94	Plasmid-mediated QnrS2 determinant in an Aeromonas caviae isolate recovered from a patient with diarrhoea. Clinical Microbiology and Infection, 2010, 16, 1005-1007.	6.0	17
95	Update on CTX-M-type Î²-lactamases. Reviews in Medical Microbiology, 2002, 13, 63-73.	0.9	15
96	Escherichia coli Producing an ACC-1 Class C Î²-Lactamase Isolated in Barcelona, Spain. Antimicrobial Agents and Chemotherapy, 2005, 49, 866-867.	3.2	15
97	Activity of ceftazidimeâ€“avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 499-504.	0.5	13
98	Campylobacter spp antibiotic susceptibility. Journal of Antimicrobial Chemotherapy, 1993, 32, 906-907.	3.0	12
99	Characterisation of plasmids encoding extended-spectrum Î²-lactamase and CMY-2 in Escherichia coli isolated from animal farms. International Journal of Antimicrobial Agents, 2008, 31, 76-78.	2.5	12
100	Detection and reporting Î²-lactam resistance phenotypes in Escherichia coli and Klebsiella pneumoniae: a multicenter proficiency study in Spain. Diagnostic Microbiology and Infectious Disease, 2008, 62, 317-325.	1.8	12
101	Characterization of a Novel IMP-28 Metallo-Î²-Lactamase from a Spanish Klebsiella oxytoca Clinical Isolate. Antimicrobial Agents and Chemotherapy, 2012, 56, 4540-4543.	3.2	12
102	Quinolone Resistance-Determining Regions of gyrA and parC in Pasteurella multocida Strains with Different Levels of Nalidixic Acid Resistance. Antimicrobial Agents and Chemotherapy, 2001, 45, 990-991.	3.2	11
103	Rates of faecal colonization by carbapenemase-producing Enterobacteriaceae among patients admitted to ICUs in Spain: Table 1.. Journal of Antimicrobial Chemotherapy, 2015, 70, 2916-2918.	3.0	11
104	Comparison of Commensal and Clinical Isolates for Diversity of Plasmids in Escherichia coli and Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	11
105	Increased resistance of enteropathogens to fluoroquinolones in Barcelona, Spain. European Journal of Clinical Microbiology and Infectious Diseases, 1993, 12, 645-646.	2.9	10
106	Bacteriophages immunomodulate the response of monocytes. Experimental Biology and Medicine, 2021, 246, 1263-1268.	2.4	10
107	Prevalence and seasonality of viral respiratory infections in a temperate climate region: A 24â€year study (1997â€“2020). Influenza and Other Respiratory Viruses, 2022, 16, 756-766.	3.4	10
108	Prospective study of bacteremia during transesophageal echocardiography. American Heart Journal, 1993, 125, 1454-1455.	2.7	9

#	Article	IF	Citations
109	Campylobacter Species: Identification and Resistance to Quinolones. Clinical Infectious Diseases, 1993, 17, 815-816.	5.8	9
110	Resistance of Salmonella and Campylobacter Species to Antimicrobial Agents. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18, 312-312.	2.9	9
111	Intra- and inter-species spread of carbapenemase genes in a non-hospitalized patient. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 1551-1555.	2.9	9
112	Ascitic fluid regulates the local innate immune response of patients with cirrhosis. Journal of Leukocyte Biology, 2018, 104, 833-841.	3.3	9
113	Characterization of the New AmpC Î²-Lactamase FOX-8 Reveals a Single Mutation, Phe313Leu, Located in the R2 Loop That Affects Ceftazidime Hydrolysis. Antimicrobial Agents and Chemotherapy, 2013, 57, 5158-5161.	3.2	8
114	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	2.5	8
115	Prevalencia en EspaÃ±a de mecanismos de resistencia a quinolonas en enterobacterias productoras de betalactamasas de clase C adquiridas y/o carbapenemasas. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 487-492.	0.5	8
116	Emergence of different resistance mechanisms inPseudomonas aeruginosa in a patient treated with imipenem. European Journal of Clinical Microbiology and Infectious Diseases, 1995, 14, 731-732.	2.9	7
117	Genetic and Kinetic Characterization of the Novel AmpC Î²-Lactamases DHA-6 and DHA-7. Antimicrobial Agents and Chemotherapy, 2014, 58, 6544-6549.	3.2	7
118	Do Prosthetic Joint Infections Worsen the Functional Ambulatory Outcome of Patients with Joint Replacements? A Retrospective Matched Cohort Study. Antibiotics, 2020, 9, 872.	3.7	7
119	Tetracycline resistance transmission in Campylobacter is promoted at temperatures resembling the avian reservoir. Veterinary Microbiology, 2020, 244, 108652.	1.9	7
120	Intraoperative Bacterial Contamination and Activity of Different Antimicrobial Prophylaxis Regimens in Primary Knee and Hip Replacement. Antibiotics, 2021, 10, 18.	3.7	7
121	Pathogenesis of Staphylococcus epidermidis in prosthetic joint infections: can identification of virulence genes differentiate between infecting and commensal strains?. Journal of Hospital Infection, 2020, 105, 561-568.	2.9	6
122	Wholeâ€genome analysis to describe a human adenovirus D8 conjunctivitis outbreak in a tertiary hospital. Journal of Medical Virology, 2021, 93, 4840-4845.	5.0	6
123	Taxonomic Identification of Different Species of the Genus Aeromonas by Whole-Genome Sequencing and Use of Their Species-Specific Î²-Lactamases as Phylogenetic Markers. Antibiotics, 2021, 10, 354.	3.7	6
124	Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 182-187.	0.5	6
125	Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2. MBio, 2021, 12, e0231521.	4.1	6
126	A New Variant of the aadE-sat4-aphA-3 Gene Cluster Found in a Conjugative Plasmid from a MDR Campylobacter jejuni Isolate. Antibiotics, 2022, 11, 466.	3.7	6

#	Article	IF	Citations
127	Prevalence of quinolone resistance mechanisms in Enterobacteriaceae producing acquired AmpC Î²-lactamases and/or carbapenemases in Spain. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 485-490.	0.3	4
128	Increased Antimicrobial Resistance in a Novel CMY-54 AmpC-Type Enzyme with a GluLeu^{217â€“218} Insertion in the Î©-Loop. Microbial Drug Resistance, 2018, 24, 527-533.	2.0	4
129	Resistencia a quinolonas y betalactÃ¡micos en Salmonella enterica, y su relaciÃ³n con mutaciones en las topoisomerasas, alteraciones en la permeabilidad celular y expresiÃ³n de un mecanismo de expulsiÃ³n activa. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2004, 22, 204-211.	0.5	4
130	Acquisition and horizontal diffusion of beta-lactam resistance among clinically relevant microorganisms. International Microbiology, 2006, 9, 79-81.	2.4	3
131	Characterization of the Genetic Environment of theblaVEB-4Gene, Associated with a Transposable Region in aProteus mirabilisClinical Isolate. Microbial Drug Resistance, 2017, 23, 833-837.	2.0	2
132	Neisseriaceae isolated from unusual sites. Clinical Microbiology Newsletter, 1993, 15, 93-94.	0.7	1
133	In-vitro activity of E-4695, a new fluoronaphthyridine antimicrobial agent. Journal of Antimicrobial Chemotherapy, 1994, 33, 1017-1023.	3.0	1
134	Speeding up antimicrobial susceptibility testing. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 331-333.	0.5	1
135	Detection of three stable genetic clones of CTX-M-15-producing Klebsiella pneumoniae in the Barcelona metropolitan area, Spain. Journal of Antimicrobial Chemotherapy, 2010, 65, 1838-1838.	3.0	0
136	Activity of ceftazidimeâ€¢avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 497-502.	0.3	0
137	Molecular characterization of OXA-48 carbapenemase-producing Klebsiella pneumoniae strains after a carbapenem resistance increase in Catalonia. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2019, 37, 82-88.	0.3	0
138	Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2020, 38, 182-187.	0.3	0
139	Recommendations of the Spanish Antibiogram Committee (COESANT) for in vitro susceptibility testing of antimicrobial agents by disk diffusion. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2022, , .	0.5	0